MedTrace Logo

Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B

NCT02288208 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-02-05

No results posted yet for this study

Summary

This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will receive either birinapant or placebo in addition to their anti-viral therapy.

Conditions

Interventions

DRUG

Antiviral Therapy (tenofovir or entecavir)

DRUG

Birinapant

DRUG

Placebo (for birinapant)

Sponsors & Collaborators

  • TetraLogic Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02288208 on ClinicalTrials.gov